Last edition
News about "Aisa Pharma"
Aisa Pharma presented Phase II RECONNOITER trial results showing AISA-021 improved attack-free days and reduced duration of Raynaud’s attacks in systemic sclerosis patients at the World Systemic Sclerosis Congress.
Aisa Pharma | 10/03/2026 | By News Bureau
Aisa Pharma Gets FDA Orphan Drug Designation for AISA-021
Aisa is developing AISA-021 for the treatment of Systemic Sclerosis (SSc), a rare disease, which impacts approximately 175,000 Americans and has the highest mortality rate of any autoimmune disease.
Aisa Pharma | 10/09/2024 | By Aishwarya | 1253
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy